Abstract 1669P
Background
Studies have shown that patients with cervical intraepithelial neoplasia (CIN) linked to human papillomavirus (HPV) experience shame and/or guilt due to the association of HPV with sexual transmission. Likewise, such feelings were also reported by cervical cancer (CC) patients. Understanding the similarities or differences in the relationship between guilt, shame, and quality of life (QoL) among these two groups might shed light on effective psychosocial interventions.
Methods
The study employed a cross-sectional design. Patients diagnosed with CIN (n=105, 11.42% CIN 1, 15.23% CIN 2, 58.09% CIN 3, 8.57% unknown) and CC (n=87, 16.09% stage 1, 17.24% stage 2, 36.78% stage 3, 8.04% stage 4, 8.04% were diagnosed with CIN that later progressed, 8.04% were uncertain about their stage at diagnosis, 5.74% unknown) who were recruited through social networks specific to CIN and CC patients completed self-report questionnaires assessing demographic information, medical history, QoL, and feelings of shame and guilt.
Results
The preliminary results revealed a significant negative association between both guilt and shame and QoL in both groups. However, no significant difference in QoL was found between CIN and CC patients (57.12, 52.26 respectively, p=0.1). Additionally, a significant higher level of guilt was reported by CIN patients (13.42) compared to CC patients (10.26) (d=0.58, p=0.0001). There was no significant difference in shame reported by CIN patients compared to CC patients (12.8, 11.37 respectively, p=0.07).
Conclusions
The findings underscore the detrimental role of shame and guilt in the perception of QoL of patients with CIN and CC. Addressing these negative feelings through targeted interventions may be crucial for improving overall well-being in these populations and enhancing their coping mechanisms. Further research involving a larger sample size may provide deeper insights into the differences and similarities between CIN and CC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HaBait Shel Bar - Israel Women's Cancer Association (RA) in collaboration with Ariel University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11